Trials / Terminated
TerminatedNCT03225287
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Ra Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zilucoplan (RA101495) | Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study. |
Timeline
- Start date
- 2017-07-17
- Primary completion
- 2021-09-07
- Completion
- 2021-10-26
- First posted
- 2017-07-21
- Last updated
- 2023-09-28
- Results posted
- 2022-10-27
Locations
12 sites across 8 countries: United States, Australia, Canada, Finland, Germany, Hungary, New Zealand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03225287. Inclusion in this directory is not an endorsement.